Payers Could Guarantee Biosimilar Market Share, FDA's Gottlieb Suggests
Executive Summary
Commissioner worries that fewer drugs may enter market in some categories because of drug development costs, and offers some post-market strategies for encouraging biosimilar development.
You may also be interested in...
Biosimilars Statistical Guidance Reflects Early Development Approach
US FDA's long-awaited draft guidance on statistical approaches for analytical similarity testing appears to echo what agency has been telling biosimilar product sponsors in private about ranking and testing reference product attributes according to criticality.
FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development
US FDA Commissioner notes that combined-phase clinical trials could be expanded beyond oncology as one way of reducing drug development costs.
Gene Therapy Platforms May Require Less Preclinical Data, Gottlieb Says
US FDA's preclinical policies should be 'more closely matched to the complexion of modern technologies,' commissioner explains.